Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
290 Leser
Artikel bewerten:
(1)

Leo Cancer Care Secures CE Mark for Marie, Advancing Upright Radiotherapy in Europe

Leo Cancer Care's CE mark approval for Marie signals a transformative shift in how radiotherapy is delivered across Europe.

CRAWLEY, England, May 20, 2026 /PRNewswire/ -- Leo Cancer Care today announced that its flagship Marie upright radiotherapy system has received CE marking, clearing the way for commercial deployment across Europe and marking a significant advancement in how radiotherapy can be delivered. The approval brings to Europe an upright treatment technology that has already gained clinical momentum in the United States.

A new approach centred on the patient

For decades, radiotherapy has required patients to lie flat and remain still, an approach that has shaped everything from system design to clinical workflows - Marie rethinks that convention entirely. By enabling treatment in an upright position, Leo Cancer Care is introducing a new paradigm: one designed to truly put the patient at the centre of care.

"This is more than a regulatory milestone - it marks the moment upright radiotherapy becomes a clinical reality for patients in Europe," said Stephen Towe, CEO of Leo Cancer Care, "Marie redefines what's possible in cancer treatment, combining human-centred design with the flexibility to support both current and emerging treatment modalities."

By enabling upright treatment delivery, Marie also has the potential to simplify treatment room design and improve operational efficiency for cancer centres.

Upright radiotherapy, designed to integrate with emerging and future therapies

Marie is the first solution of its kind to combine upright patient positioning with a beam-agnostic architecture compatible with multiple particle therapy modalities. This positions Marie not just as an innovation, but as a future-ready platform for next-generation radiotherapy.

Key potential benefits include:

  • A more natural and comfortable treatment experience for patients
  • Enhanced treatment delivery capabilities, including support for online adaptive and arc therapy
  • Improved accessibility for institutions unable to implement traditional particle therapy solutions
  • A flexible platform designed to support future advances in radiotherapy

Bringing this advanced treatment modality to Europe

CE marking confirms that Marie meets the highest European standards for safety, performance and clinical readiness - the result of years of research, engineering and clinical collaboration with partners across the radiation oncology ecosystem.

Centre Léon Bérard, a hospital that is entirely dedicated to cancer care and research, has been a long-term research partner of Leo Cancer Care. Following CE mark approval, the collaboration will now expand to focus on anatomical imaging and positioning in the upright orientation using Marie's upright CT capabilities.

A pivotal advancement in refining the frontiers of hadrontherapy

For Leo Cancer Care, this milestone is just the beginning, as European installations have begun with Centro Nazionale di Adroterapia Oncologica (CNAO) in Italy, with the aim of commencing treatments before the end of the year.

The Director General of the Centro Nazionale di Adroterapia Oncologica, Dr. Sandro Rossi, remarked on the collaboration with Leo Cancer Care (LCC):

"The integration of the LCC upright positioning system into our clinical workflow marks a transformative milestone for CNAO. By pairing LCC's innovative technology with our horizontal multi-ion beam, we are introducing a sophisticated new modality designed to optimize treatment precision and fundamentally enhance clinical throughput.

This synergy between upright positioning technologies and our clinical expertise does more: it reinforces our commitment to delivering accessible, human-centric, individually tailored and advanced oncological solutions. We look forward to working closely with the Leo Cancer Care team as we move toward installation, commissioning and first patient treatments."

With regulatory approval now in place, Leo Cancer Care is working with other leading cancer centres across Europe to bring upright radiotherapy into clinical practice, accelerating adoption of a solution designed to prioritise both treatment precision and patient experience.

Photo: https://mma.prnewswire.com/media/2984245/LEOCC_Marie.jpg
Logo: https://mma.prnewswire.com/media/2740062/5980168/Leo_Cancer_Care_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/leo-cancer-care-secures-ce-mark-for-marie-advancing-upright-radiotherapy-in-europe-302777824.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.